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Abstract: Pyridoxal 5′-phosphate (PLP) is the most important cofactor of vitamin B6-dependent
enzymes, which catalyses a wide range of essential body functions (e.g., metabolism) that could
be exploited to specifically target highly metabolic cells, such as tumour metastatic cells. However,
the use of PLP as a simultaneous coating and targeting molecule, which at once provides colloidal
stability and specific biological effects has not been exploited so far. Therefore, in this work iron
oxide nanoparticles (IONPs) were coated by PLP at two different pH values to tune PLP bonding
(e.g., orientation) at the IONP surface. The surface study, as well as calculations, confirmed different
PLP bonding to the IONP surface at these two pH values. Moreover, the obtained PLP-IONPs
showed different zeta potential, hydrodynamic radius and agglomeration state, and consequently
different uptake by two metastatic-prostate-cancer cell lines (LnCaP and PC3). In LnCaP cells, PLP
modified the morphology of IONP-containing intracellular vesicles, while in PC3 cells PLP impacted
the amount of IONPs taken up by cells. Moreover, PLP-IONPs displayed high magnetic resonance
imaging (MRI) r2 relaxivity and were not toxic for the two studied cell lines, rendering PLP promising
for biomedical applications. We here report the use of PLP simultaneously as a coating and targeting
molecule, directly bound to the IONP surface, with the additional high potential for MRI detection.
Keywords: iron oxide nanoparticles; cellular uptake; magnetic resonance imaging; pyridoxal
5′-phosphate; surface functionalization
1. Introduction
The biomedical use of nanoparticles (NPs) strongly depends on their colloidal stability in
physiological conditions. Their stabilization in aqueous medium is achieved by coating NPs with
various biocompatible molecules. Large polymers (e.g., polyethylene glycol, PEG) or sugars (e.g.,
dextran, chitosan) are among the most commonly used coatings for the steric stabilization of NPs [1].
However, the final hydrodynamic diameter (dH) of such NPs tends to be very large (typically up
to hundreds of nanometers), especially after the addition of targeting moieties or drugs. Therefore,
charged molecules, which provide electrostatic stabilization, are often preferred, because they are
small and therefore allow the maintenance of an overall diameter of NPs that is as small as possible.
This small size is highly needed to overcome specific biological barriers, for instance to reach lymph
node metastases, or to increase the amount of NPs inside small volumes (e.g., metastases) for increased
therapeutic efficacy and/or imaging capability. The coating not only determines the size of the NPs,
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but also, via specific chemical groups and their charge, the affinity of the coating to the NPs’ surface,
and the possibility to further couple the NPs with targeting molecules and/or drugs. Consequently,
the choice of the coating molecule is crucial, not only because it determines the surface properties
of the NPs (chemical groups, size, charge), but also because in turn it directly affects the biological
behaviour of NPs, especially their cellular uptake [2], biodistribution [3], blood circulation [4] and
metabolism [5]. Among these biological effects, the biodistribution of NPs has received particular
attention. Coupling the NPs with a targeting agent in order to specifically deliver NPs to body regions,
such as tumours, dramatically enhances their clinical utility [6–8]. Various approaches have been
reported for the active targeting of NPs, especially those which use antibodies, aptamers and smaller
molecules. In particular, the use of small targeting molecules, or even the use of one molecule as a
simultaneously targeting and coating molecule, would significantly decrease the overall size of NPs.
Unfortunately, this combination is so far not fully exploited.
Among the numerous small bio-molecules, pyridoxal 5′-phosphate (PLP), which is the
phosphorylated form of pyridoxal found in vitamin B6, is a very promising molecule to coat and
target NPs, because among the molecules present in vitamin B6, PLP has the most impact in the body
(it is the cofactor of most vitamin B6-dependent enzymes, catalysing a large range of biochemical
reactions) [9]. PLP-dependent enzymes are especially involved in essential cellular processes, as for
instance in the biosynthesis of amino acids or neurotransmitters, in the synthesis of heme, or in the
regulation of important genes (e.g., glucocorticoid hormones, albumin) [10]. PLP has therefore an effect
on the regulation of essential body functions, especially cardiovascular, metabolic, immunologic and
homeostatic functions. For all these reasons, it is of interest to use PLP as a coating of NPs, especially
of iron oxide NPs (IONPs), which are extensively studied for their use as medical diagnostic and
therapeutic agents.
PLP is not only biocompatible, but it has also four chemical groups (phosphoryl, pyridinium
nitrogen, phenolic and aldehyde groups, see the chemical structure of PLP in Figure 1) which render
this molecule highly bio-active [11]. This versatility of chemical groups has been exploited to bind
PLP on the surface of various types of NPs. Usually, the phosphate group has been used to bind PLP
to the NP surface, while the aldehyde and/or phenolic groups have been employed to couple the
PLP-coated NPs with anti-cancer drugs. In other words PLP is typically playing the role of a link
between the NP and the active molecule [12]. Apart from their use as linking groups, the former
two chemical groups have also been used to chelate metal ions, especially at the surface of gold
NPs [13], silica NPs, oxidized carbon nanotubes or silica-coated IONPs [14]. Therefore, PLP has been
mainly used as a linker and chelating agent. However, various chemical groups of PLP—if in the
deprotonated state, i.e., charged—could be used to electrostatically stabilize NPs and could therefore
in the suitable coating conditions enable the use of PLP as a coating molecule. Furthermore, given that
PLP plays the essential and very specific functional roles in the human body given above, PLP could
be bound to the surface of NPs to trigger specific biological effects and to give NPs interesting features.
For example, the importance of PLP in the metabolism could be exploited to specifically target NPs
to highly metabolic cells, such as cancer cells and especially metastatic cells. Unfortunately, both the
coating of NPs with PLP to stabilize them and their use as a targeting agent has not been studied so far.
In the present study, we coated IONPs with PLP using a one-step coating reaction at two different
pH values, 7.0 and 2.5, in order to differently orient the PLP molecule at the IONPs’ surface, and thus
tune the behaviour of IONPs that are in contact with biological matter, while preserving the targeting
activity of PLP bound to the IONPs’ surface. In order to study the influence of the PLP orientation at the
IONPs’ surface, the surface of PLP-coated IONPs was characterized by spectroscopy (Fourier transform
infrared spectroscopy (FTIR), X-ray photoelectron spectroscopy (XPS) and UV-visible spectroscopy).
In order to evaluate the potential use of PLP as a coating molecule, we measured the zeta potential
and studied the agglomeration state of PLP-coated IONPs by transmission electron microscopy (TEM)
and by dynamic light scattering (DLS) in both water and two biological media. We also measured the
magnetic resonance imaging (MRI) relaxivity of PLP-IONPs to evaluate their potential for diagnostics
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by MRI. Moreover, we investigated their cellular uptake by two metastatic-prostate-cancer cell lines
(LnCaP and PC3) and their toxicity in order to explore the possibility of using PLP on the IONP’s
surface as a coating molecule and simultaneously as a targeting agent for controlling the biological
behaviour of PLP-IONPs.
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condition the surface of IONPs can be functionalized by PLP due to the electrostatic interactions of
the opposite charges. The deprotonated phosphoryl group was found by density functional theory
(DFT) calculations to have a binding energy of 3.54 eV (Figure 2a), while the deprotonated phenolic
group adsorbs in a bidentate fashion together with the neighboring aldehyde group with 1.94 eV
(Figure 2b). Attempts to adsorb only the phenolic group were unsuccessful, however the aldehyde
group could be adsorbed separately and has a binding energy of 1.00 eV (Figure 2d). Assuming
that the binding energies are additive, this means that the phenolic group alone contributes about
0.94 eV binding energy. All these suggest stronger bonding of the deprotonated phosphoryl group,
which involves all phosphoryl terminations, leading to multidentate bonding (Figure 2a). In addition,
the adsorption of the pyridinium nitrogen on the surface of IONPs could not be computed, because
the deprotonated phosphoryl group always adsorbs first. However, in the other coating condition,
at pH 2.5, the surface of IONP is strongly charged (ξ is about +50 mV) and thus able to attract: (A) the
partially deprotonated phosphoryl group (Figure 2c), but also (B) protonated phenolic and aldehyde
groups that absorb together as bidentate in a configuration very similar to the ones of the bidendate
deprotonated phenolic and aldehyde groups shown in Figure 2b. The bonding energies of these two
groups, (A) and (B), were found by DFT calculations to be more comparable (1.74 eV and 0.82 eV,
respectively) than at pH 7.0. Thus, at both coating pH values, the bonding of PLP to the surface of the
IONPs occurs by preferential adsorption of the phosphoryl group. However, the phosphoryl group
bonding is much more favorable at pH 7.0 than at pH 2.5. This suggests that the bonding of PLP to the
IONPs’ surface proceeded more via the fully deprotonated phosphoryl group at pH 7.0, and via both
partially deprotonated phosphoryl and aldehyde groups at pH 2.5.
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Figure 2. Relaxed adsorption configuration of (a) the deprotonated phosphoryl group, (b) the deprotonated
phenyl group bidentate with the aldehyde group, (c) the protonated phosphoryl and (d) aldehyde groups
of PLP on the (110) surface of iron oxide used to compute the binding energies in the studied cases.
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2.2. Surface Characterization
The surface of the uncoated and both PLP-coated IONPs (PLP-IONPsN and PLP-IONPsA) were
studied by XPS and the obtained elemental composition (Fe, O, C, N and P) of these samples is given
in Table S1. The presence of PLP on the surface of IONPs in both coated samples is indicated by the
detection of P 2p XPS peaks (1.1 at% and 1.3 at% of P were found in PLP-IONPsN and PLP-IONPsA,
respectively) in coated as compared to uncoated IONPs (Table S1). The XPS spectra, overall (a) and
the Fe 2p, N 1s, C 1s and P 2p peaks (b to e), of uncoated and coated IONPs are shown in Figure S1.
For all samples, the Fe 2p3/2 was found at 710 eV (Figure S1b), which is in agreement with previous
reports. [19] Moreover, the bonding energy of the P 2p bond is considered as a good indicator of the
attachment of the phosphoryl group, since deprotonation of one or both P–OH terminals can be easily
seen by P 2p shifts to 133.6 eV and 133.2 eV, respectively [19,20]. Indeed, the P 2p bonding energy for
the fully deprotonated PLP in the sample PLP-IONPsN was found at 133.28 eV (Figure S1e), while for
PLP-IONPsA it was found at 133.5 eV. The last value is higher than for the PLP-IONPsN sample, but
still lower than for the protonated PLP (134.1 eV), suggesting that PLP is partially deprotonated due to
the possibility for PLP to form intermolecular bonding between molecules on the surface of either the
same IONP or between different IONPs [20].
Additional information on the attachment of PLP to the surface of IONPs was obtained by FTIR
(Figure 3). In particular, the FTIR spectra in the 900–1500 cm−1 region, containing the characteristic
P=O and P–O stretching vibrations, is given in Figure 3. As expected, the characteristic peaks at
1383 cm−1, which is typical for the γ-Fe2O3 composition of IONPs [16], were observed in all samples.
Also, the characteristic P=O and P–O–H bands around 1250 and 920 cm−1, respectively, were not
observed in the coated samples. Instead, a broad band from ~950 to ~1200 cm−1 was found in both
coated samples and this is typically associated with multidentate bonding [21], which is in agreement
with the above given XPS results.
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The influence of PLP on the surface properties of IONPs was assessed by measuring the zeta
potential (ξ) of uncoated and PLP-coated IONPs. The ξ values were firstly measured in water, which
allowed us to assess the effect of the difference in PLP coating on the surface properties of two
PLP-coated IONPs without the interference of proteins. As expected, we found that the ξ in water
changed between uncoated and PLP-coated IONPs, confirming that the IONPs’ surface is coated
with PLP molecules (Table 1). In addition, a difference in ξ was observed between PLP-IONPsN
and PLP-IONPsA, confirming that the binding of PLP to the surface of IONPs is different between
the two types of PLP-coated IONPs. More precisely, the ξ of PLP-IONPsN was more negative than
that of PLP-IONPsA. This is in agreement with the above given results, especially with the results of
bonding calculations, which suggested that PLP preferentially bonds to the surface of IONPs via the
deprotonated phosphoryl group at pH 7, but via both protonated phosphoryl and phenolic groups at
pH 2.5, leading to more negative ξ in the first case.
Table 1. Hydrodynamic diameter (dh) and zeta potential (ξ) measured by DLS of 100 µgFe mL−1
uncoated IONPs, PLP-IONPsN and PLP-IONPsA measured in water (pH ~7.0), in Roswell Park
Memorial Institute (RPMI) medium and in Dulbecco’s Modified Eagle Medium (DMEM) (pH ~7.6).
dh in Water
(nm)
dh in RPMI
(nm)
dh in DMEM
(nm)
ξ in Water
(mV)
ξ in RPMI
(mV)
ξ in DMEM
(mV)
IONPs 23 ± 8 114 ± 39 1352 ± 562 5.0 ± 2.0 −7.6 ± 0.6 −9.2 ± 0.7
PLP-IONPsN 1065 ± 296 1893 ± 440 1657 ± 552 −16.7 ± 0.6 −7.6 ± 0.7 −7.5 ± 0.6
PLP-IONPsA 1592 ± 537 1752 ± 379 1685 ± 1074 −3.9 ± 0.8 −7.9 ± 0.8 −8.0 ± 0.9
For possible biomedical applications, the characterization of IONPs in medium, i.e., in the presence
of proteins, is crucial, since proteins present in the biological environment can change the surface and
the ξ of NPs [22]. The ξ was therefore measured in Roswell Park Memorial Institute (RPMI) medium
and Dulbecco’s Modified Eagle Medium (DMEM; Table 1), which were the media used in the cell
experiments performed in the present study. We found that the ξ in the media were different from the
ξ measured in water, confirming that proteins covered the IONPs’ surfaces as expected and modified
their surface charge. Furthermore, the ξ measured in medium was about −8 mV, regardless of the
nature of the IONPs’ surface and the media. Consequently, the proteins present in the medium tended
to homogenize the surface charges among samples, hiding the inherent surface charge of uncoated
and PLP-coated IONPs.
We also evaluated the optical properties of uncoated and PLP-coated IONPs by measuring
their absorbance spectra by ultraviolet (UV)-visible spectroscopy (Figure S2). Since UV visible
absorbance strongly depends on the environment surrounding IONPs, we measured the spectra
in water (Figure S2a), as well as in protein-containing RPMI (Figure S2b) and DMEM (Figure S2c)
media. Firstly, for uncoated IONPs, we found that the major peak around ~380 nm found in water
shifted towards higher wavelengths when measured in RPMI and DMEM (Figure S2d). This has been
previously reported for IONPs after their coverage by proteins [23], suggesting that proteins from the
media bind to the surface of IONPs. Such peak shifts were also observed in both PLP-IONPsA and
PLP-IONPsN (Figure S2e,f). Differences in absorbance intensities were also observed between the
spectra of all samples measured in RPMI and DMEM as compared to water, confirming the presence
of proteins in the environment [24].
2.3. Stability of PLP-Coated IONPs
The agglomeration state and the morphology of uncoated and PLP-coated IONPs were firstly
studied by TEM. TEM micrographs of PLP-IONPsN and PLP-IONPsA in water (see Figure 1b,c,
respectively) showed agglomerates with irregular shape for both coated IONP samples as compared
to uncoated IONPs. Moreover, these agglomerates were larger in PLP-IONPsA (up to 1.5 µm) than
in PLP-IONPsN (typically smaller than 500 nm). Such behaviour can be related to the probably low
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electrostatic repulsion interactions between the PLP-IONPsA caused by the relatively low negative
charges (ξ was −3.9 ± 0.8 for PLP-IONPsA), which were not sufficient to provide colloidal stability.
In order to study the colloidal stability of IONPs in aqueous suspensions, dh of uncoated and
PLP-coated IONPs were measured in water by DLS. The obtained values are given in Table 1. The dh
of PLP-coated IONPs was larger than the uncoated IONPs, suggesting that IONPs agglomerated after
the surface modification by coating, as observed in the TEM micrographs. However, some differences
between TEM observations in dried samples and dh measured in water were expected due to the
different state of the studied samples, i.e., dried powders and aqueous suspension. Furthermore,
the dh of PLP-IONPsN was smaller than the dh of PLP-IONPsA, indicating that PLP-IONPsA were
more agglomerated than PLP-IONPsN. This is consistent with the agglomerates observed by TEM
(Figure 1b,c). Similar values of dh for all three types of IONPs were also found by two other size
measurement methods, i.e., by the second DLS instrument and by centrifugal force (Figure S3).
It is known that NPs in biological environments are not only in aqueous medium, but are also in
the presence of biomolecules, especially proteins. Importantly, the surface of NPs has been previously
shown to be modified with proteins, forming the so-called protein corona [22]. In fact, the protein
corona can change the aggregation state of NPs, which in turn alters their interaction with cells [25–29],
their biodistribution [30,31] and their toxicity [32,33]. Therefore, in order to study the influence of
the presence of proteins on the colloidal behaviour of IONPs, we measured dh in RPMI medium
and DMEM (Table 1). First of all, dh measured in the presence of proteins in the two studied media
were larger than dh measured in water, suggesting that the IONPs’ agglomeration was enhanced in
biological medium in the presence of proteins. This was the case for uncoated and PLP-coated IONPs,
confirming that proteins interact and bind to the surface of IONPs, modifying their aggregation state.
In addition, PLP-IONPsN and PLP-IONPsA were agglomerated in both media and this behaviour was
found to be more pronounced in both media than in water. This was expected due to the presence of
the highly active chemical groups of PLP on the surface of PLP-coated IONPs, which can interact with
biomolecules present in the environment, such as with proteins present in both media. However, for
uncoated IONPs, the agglomeration was observed only in one medium, DMEM. In fact, the difference
between RPMI and DMEM lies in their different salt and protein concentrations, which were shown to
strongly influence the colloidal stability of NPs, their cytotoxicity and their cellular uptake [34]. These
differences in salt and protein concentrations could therefore be the cause of the different stabilities of
IONPs observed between the two media. In addition, the stability is not only medium-dependent, but
also dependent on the coating type, i.e., the chemical nature of the surface upon coating, which drives
the interaction with the bio-environment, which was also previously reported [34].
2.4. Toxicity Evaluation
The in vitro preliminary toxicity of different concentrations of uncoated and PLP-coated IONPs
was measured on two human prostate cancer cell lines: (i) early metastatic cells from lymph
nodes (LnCaP cells) and (ii) late metastatic cells from bones (PC3 cells). The toxicity of all
samples was first assessed by the with the 3-(4,5-dimethylthiazol-2-yl)-5-(3-carboxymethoxypenyl)-2-
(4-sulfophenyl)-2H-tetrazolium (MTS) test on LnCaP cells (Figure S4). All measured cell viabilities
were above 75% (Figure S4), suggesting that uncoated and PLP-coated IONPs were not toxic for LnCaP
cells up to a concentration of 100 µgFe mL−1 and that PLP is well tolerated by cells, as expected.
However, due to the high variability of the cell viabilities measured with the MTS assay, no difference
could be extracted between the studied samples. In fact, in absorbance-based toxicity tests, such as
the MTS test, the absorbance of IONPs can modify the toxicity results, which can be corrected with
our previously developed method [35]. Unfortunately, this method could not be applied in this study,
because after few hours of incubation, 100% of the administrated IONPs were deposited and the
IONPs fraction which stuck to the cells after the removal of the supernatant could not be estimated.
Such issues with NP absorbance were not present in the fluorescence-based toxicity assays, such as the
Annexin V and propidium iodide (PI) assays. We therefore also studied the toxicity of all samples on
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the LnCaP and PC3 cell lines by measuring the fluorescence of Annexin V and PI) by flow cytometry.
In LnCaP cells, we found lower toxicities of uncoated and PLP-coated IONPs with the Annexin V/PI
assay (Figure 4a) as compared to the MTS test. The Annexin V/PI assay performed on LnCaP cells
showed that the PLP coating decreases the toxicity of IONPs (Figure 4a), while all viabilities of PC3
cells (Figure 4b), which are less sensitive to external stimuli and therefore more resistant than LnCaP
cells, were ~100%, regardless the type of IONPs and the IONP concentration. Therefore, by decreasing
the toxicity of IONPs in vitro, PLP, which is involved in essential in vivo biological functions and is
known to be biocompatible, is a promising molecule for its use in biomedical applications.
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10, 50 and 100 µgFe mL−1) of uncoated IONPs, PLP-IONPsN and PLP-IONPsA measured with the
Annexin V/PI assay. The cell viabilities are percentages of viable cells treated with IONPs normalized
with the number of viable cells without IONPs (0 µgFe mL−1). 10 µM of Staurosporine and 2 mM of
H2O2 were used as positive controls.
2.5. Interaction of IONPs with Cells
In order to study the potential use of PLP simultaneously as a molecule for targeting tumour cells
and to exploit the role of PLP in essential body functions such as metabolism, we investigated the
influence of PLP on the cellular uptake of IONPs. Firstly, we studied the uptake of PLP-IONPsN and
PLP-IONPsA at different concentrations in LnCaP and PC3 cells by extracting additional information
from the above-presented flow cytometry results. We measured the forward scattered (FSC) light,
which is proportional to the cell surface area and therefore their size, and the side scattered (SSC)
light, which is a measure of the cell granularity and intracellular structure complexity. In fact, it was
recently shown that SSC can be used to measure the amount of NPs taken up by cells, because NP
uptake modifies the intracellular structure and increases cell granularity [36]. The SSC in function
of the FSC for LnCaP and PC3 cells is shown in Figures S5 and S6, respectively, where each point
represents a cell. We can observe an increase of points/cells with higher SSC values with an increase
in IONP concentration (for instance the first vs. the last row in Figures S5 or S6), meaning that these
cells have higher granularity. If we plot the sum of the number of cells (cell counts) found for each SSC
value in Figures S5 and S6, we obtained the result showed in Figure S7. Indeed, the broadening of
the SSC-count’s peak and the shift of the peak towards higher values for higher IONP concentrations
in both LnCaP and PC3 cells were observed for both uncoated and PLP-coated IONPs. Furthermore,
the largest shift in the SSC towards higher values, and therefore the highest cell granularity, was
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observed for PLP-coated IONPs in PC3 cells. Therefore, the uptake of PLP-coated IONPs in PC3 cells
was higher than that of uncoated IONPs.
In order to study the differences seen in the uptake in more details, we did a TEM study, which
allowed us to locate IONPs inside cells and to observe the morphologies of cells and vesicles. For this
purpose, we prepared 50-nm thick sections of cells, and stained it with uranyl acetate to enhance the
cellular contrast, which was examined by TEM. Representative TEM micrographs of these 50 nm-thick
sections of LnCaP and PC3 cells incubated with 100 µgFe mL−1 of uncoated and PLP-coated IONPs
are shown in Figure 5 and Figure S8. Firstly, in LnCaP cells, the amount of IONPs taken up was
similar between uncoated and PLP-coated IONPs, as well as between PLP-IONPsN and PLP-IONPsA.
However, the vesicles containing IONPs were different between uncoated IONPs and PLP-coated
IONPs. For uncoated IONPs, these vesicles were found already deep in the intracellular space, while
the vesicles containing PLP-IONPsN and PLP-IONPsA were in both cases located rather at the edges of
the cells. Therefore, the uptake process seemed to be more advanced and therefore faster for uncoated
IONPs as compared to PLP-coated IONPs. In addition, uncoated IONPs were mostly found in small
structured vesicles (~1 µm in diameter), but PLP-coated IONPs were also found in empty vesicles with
much larger diameters. The morphology of the vesicles was also the major difference found between
PLP-IONPsN and PLP-IONPsA; while vesicles containing PLP-IONPsN were smaller than 1 µm in
diameter and mostly structured (see arrows in Figure 5e), they were much larger (>1–5 µm), as well
as unstructured and empty for PLP-IONPsA (see arrows in Figure 5g). In LnCaP cells, we therefore
essentially found differences in the morphological properties of vesicles containing IONPs, rather
than in the amount of IONPs taken up, which could be due to a difference in the uptake mechanism
involved between uncoated and PLP-coated IONPs, but also between PLP-IONPsN and PLP-IONPsA.
In PC3 cells, the amount of uncoated IONPs found inside cells was much smaller than in LnCaP
cells, as also seen above with the SSC shift in the flow cytometry results. In addition, IONPs were
hardly distinguishable from the intracellular dark structures (see arrows in Figure 5d). Interestingly,
the amount of PLP-IONPsN and PLP-IONPsA found inside PC3 cells was much larger than that of
uncoated IONPs, that is also in agreement with the above given results from the flow cytometry. PLP
therefore increases the amount of IONPs taken up in PC3 cells, which was not the case in LnCaP
cells, suggesting that PLP modifies the interaction of IONPs specifically with PC3 cells. Furthermore,
the uptake of PLP-IONPsN was similar to that of PLP-IONPsA, both being more advanced than in
LnCaP cells. IONPs were very rarely found close to the cellular surface, but rather deep inside the cells
and even around the nucleus. In addition, the morphology of the vesicles containing PLP-coated IONPs
was similar between PLP-IONPsN and PLP-IONPsA; in both coated samples, IONPs were located in
large vesicles with diameters of ~2–4 µm (see arrows in Figure 5f,h). However, a large difference in
the vesicle morphologies was found between uncoated and PLP-coated IONPs. Consequently, in PC3
cells, the uptake seems to be similar between PLP-IONPsN and PLP-IONPsA, but different from that
of uncoated IONPs. The difference mainly lay in the amount of IONPs found inside cells, even though
differences in the morphology of vesicles were also observed between uncoated and PLP-coated
IONPs. This was not the case in LnCaP cells, in which the intracellular amounts of uncoated and
PLP-coated IONPs were similar, but the vesicle morphologies were different. Consequently, we show
that the uptake is cell specific, as previously reported for folic acid coated IONPs [37], and that PLP
modulates the uptake of IONPs in both LnCaP and PC3 cells. More precisely, PLP modified the uptake
of IONPs from a mechanistic point of view in the first cell line, but both in a mechanistic manner and
by changing the amount of IONPs taken up in the second one.
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The differences observed in the amounts of all studied samples taken up by cells and the morphology
of the vesicles containing these IONPs could be due to a difference in IONPs and/or in the uptake
mechanism. In fact, the major difference between LnCaP and PC3 cells resides in the different expression
of the prostate specific membrane antigen (PSMA) [38,39]. While PC3 cells do not express PSMA, LnCaP
cells do. Interestingly, small molecules (e.g., S,S-2-(3-(5-amino-1-carboxypentyl)-ureido)-pentanedioic
acid, ACUPA) have been used to direct NPs to PSMA-positive prostate cancer cells [40,41]. However,
the chemical structures of these molecules are very different to that of PLP, suggesting that the
differences observed in the uptake of PLP-IONPs between LnCaP and PC3 cells are not mediated
by the presence and the absence of PSMA, respectively. Therefore, the observed differences in
the uptake between the studied samples could rather be caused by the samples’ physico-chemical
properties, such as the different agglomeration states and surface charges described above between
the two PLP-coated IONPs, but also between uncoated and PLP-coated IONPs, which could be at
the origin of these different uptake mechanisms. It is known that PLP serves as a coenzyme for
numerous enzymatic reactions (e.g., amino acid biosynthesis and catabolism via their transamination,
gluconeogenesis, hemoglobin synthesis, etc.), [10] which occur in the intracellular space. PLP was
shown to be transported in the blood by being attached to albumin in order to reach the tissues where
these enzymatic reactions occur [42]. However, while the non-phosphorylated form pyridoxal is
known to cross the cellular membrane [43–45], only very little is known about the cellular uptake of
the membrane impermeable PLP [46]. It seems that the cellular uptake of PLP is carrier-mediated [44],
but deep knowledge of the transporters involved in these mechanisms is lacking [43]. Interestingly,
one of the rear studies, which investigated the uptake of PLP in cells, showed that PLP is rapidly taken
up by human red blood cells [47]. Here we show for the first time that PLP-coated NPs are taken up
by tumour cells in a different manner than uncoated IONPs. While IONPs are known to be taken up
via the endocytosis-mediated pathway [48,49], the uptake of PLP-coated IONPs could be mediated
via the poorly-investigated carrier that is involved in the uptake of the membrane-impermeable PLP.
Furthermore, we show that the orientation of PLP at the IONPs’ surface modifies the uptake of IONPs,
which was especially found in PC3 cells, which suggests that the uptake not only depends on the
chemical nature of the coating, but also on the orientation of this molecule on the surface of IONPs.
Our results are a step forward in the understanding of the cellular uptake of PLP bound to NPs and
show that PLP controls the interaction of IONPs with cells, as previously reported for other types of
coatings [34,50–54]. This could be used to modulate the cellular uptake of NPs and further studies
should investigate how PLP at the IONPs’ surface affects other biological effects, such as the NPs’
biodistribution, blood circulation and metabolism.
2.6. Potential as an MRI Contrast Agent
IONPs are known to be very promising as contrast agents for MRI, because they shorten the
relaxation time of neighbouring protons, especially the transverse relaxation time T2, therefore they
are considered as T2 contrast agents. In order to evaluate the potential use of PLP-coated IONPs for
diagnostics by MRI, we measured their longitudinal (r1) and transverse (r2) relaxivities. Figure 6a,b and
c show the r1 and r2 values, as well as the relaxivity ratio r2/r1 for uncoated IONPs, PLP-IONPsN and
PLP-IONPsA measured at room temperature in a clinical 3 T MRI scanner. Firstly, we measured lower
r1 values for PLP-coated IONPs, as compared to uncoated IONPs. Previous studies have reported that
the addition of a coating molecule, i.e., an increase of the size, reduces the r1 relaxivity [55]. The most
important parameter for IONPs, which are classified as T2 contrast agents, is the r2 relaxivity. This
parameter reflects the shortening of the relaxation rate (1/T2) as function of a IONPs concentration,
meaning that higher concentrations of IONPs accelerate the spin–spin relaxation time of adjacent water
molecules, resulting in the faster decay of the MRI signal. We measured a smaller r2 relaxivity for
PLP-coated IONPs as compared to uncoated IONPs, which was previously observed after the addition
of a coating, i.e., an increase of the size upon coating, which could make the T2 shortening capabilities
less efficient [55–57]. Furthermore, we have found above agglomerates in both PLP-IONPsN and
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PLP-IONPsA, which were previously shown to affect the r2 relaxivity [58]. However, the obtained
r2 values of 559 mM−1s−1 and 894 mM−1s−1 for PLP-IONPsN and PLP-IONPsA, respectively, were
unexpectedly high for coated IONPs. This could be explained by the relatively thin PLP coating.
Indeed, the obtained r2 values for PLP-IONPsN and PLP-IONPsA are still much higher than in most
of the reported IONPs coated with larger molecules (e.g., polyethylene glycol, dextran), which had
at 3 T r2 values between 50–164 mM−1s−1 [59–61]. Thus, our results confirm the importance of the
coating thickness for the r2 relaxivity of IONPs.
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Figure 6. Magnetic resonance imaging (MRI) longitudinal r1 (a) and transverse r2 relaxivity (b) and
the relaxivity ratio, r2/r1 (c) measured at room temperature at 3 T for uncoated IONPs, PLP-IONPsN
and PLP-IONPsA.
the high r2 value, the r2/r1 ratio was two times larger fo PLP-coated IONPs than uncoated
IONPs. It has been previously shown that decreasing the oating thickness i creases the r2/r1 r tio [55].
In fact, contrast agents with both large r2 and r2/ 1 ratios are necessary for th ir use as efficient T2
contras agents. Cons quently, given he h gh r2 and r2/ 1 ratio that we measured for PLP-coated
IONPs, the u e of PLP as a small coating and at the same time targeting mol cule is highly beneficial
for their superior propert es fo T2-w ighted imaging as compared to products found in the literature.
3. Materials and Methods
3.1. Synthesis of IONPs
IONPs were synthesized following a protocol modified from Bonvin et al. and described
previously [15]. Briefly, IONPs were synthesized by co-precipitation in combination with a hydrothermal
treatment performed at 120 ◦C for 15 h. At the end of the synthesis, the obtained IONPs were kept in
10 mM HNO3 at 4 ◦C.
3.2. Coating of IONPs with PLP
Two types of coated IONPs were prepared:
(1) PLP-IONPsN: An IONP suspension (in 10 mM HNO3), which contained 50 mg of IONPs
(35 mg Fe) was mixed with water to result in 35 mL of suspension. The pH of the IONP suspension
was adjusted to 7 with ~700 µL of 0.25% ammonia solution. The IONPs were separated on a strong
magnet and the supernatant was removed; 15 mL of water was added and the IONP suspension was
sonicated for 6 min to remove IONPs agglomerates. The pH of the resulting IONP suspension was 7.0.
(2) PLP-IONPsA: An IONP suspension (in 10 mM HNO3), which contained 50 mg of IONPs
(35 mg Fe) was mixed with water to result in 10 mL of suspension. The pH of the resulting IONP
suspension was 2.5.
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For both PLP-IONPsN and PLP-IONPsA, 68 mg of pyridoxal phosphate (FluoroChem, 98%
purity) were dissolved in 15 mL water. 5 mL of the dissolved pyridoxal phosphate were added to the
IONPs suspensions, which were rotated for 5 min with a rotator (tube rotator from VWR International)
placed on a shaker at 500 rpm. This procedure was repeated until the whole solution of pyridoxal
phosphate was added to the IONP suspension. The volume was adjusted to 35 mL with water to
approximately reach a final concentration of 1 mgFe mL−1 and the IONP suspensions were rotated for
30 min with the rotator placed on the shaker at 500 rpm. After 30 min, the IONP suspensions were
dialyzed (Spectra/Por®; 12–14 kDa) against water for 72 h by changing the dialysis solution every
10–12 h, and finally, the obtained suspensions were stored at 4 ◦C.
3.3. Characterization of PLP-Coated IONPs
For transmission electron microscopy (TEM), 5 µL drops of IONP suspensions were deposited on
holey carbon grids (Plano GmbH, Wetzlar, Germany) placed onto absorbing filter paper and left to
dry at room temperature. TEM micrographs were taken with a Talos F200X FEI electron microscope
(FEI, Gräfelfing, Germany) operated at an acceleration voltage of 200 kV and coupled to a CMOS-based
FEI CETA 4000 × 4000 camera (FEI, Gräfelfing, Germany). The primary particle size of uncoated
IONPs (diameter of IONPs, in the text referred as TEM diameter) of 1000 IONPs was measured manually
from randomly taken TEM micrographs using ImageJ software (the National Institutes of Health,
Bethesda, MD, USA).
For all samples the iron concentration was determined by ICP-EOS with ICP-EOS 9000
(Shimadzu, Duisburg, Germany). For this purpose, a volume of 80 µL of IONPs stock suspension of
as-synthesized-IONPs was mixed with 920 µL of 6 M HCl. After three days, the IONPs were fully
dissolved and 500 µL of the obtained solution containing the dissolved Fe-ions was diluted in 2.5 mL
of water.
The hydrodynamic diameters (dh) and the zeta potentials of 1 mL IONP suspension at a
concentration of 100 µgFe mL−1 in water, RPMI medium and Dulbecco’s Modified Eagle Medium
(DMEM) were measured at room temperature in acrylic cuvettes (Sarstedt, Nümbrecht, Germany)
with a Zetasizer Nano ZS (Malvern Instruments, Worcestershire, UK). The reported values of dh were
obtained from the average of 3 × 12 measurements. The refractive index of γ-Fe2O3 and absorbance
were set to 2.95 and 0.1, respectively. The dh of IONP suspension in water were also measured by
laser diffraction with the Mastersizer 3000 (Malvern Instruments, Worcestershire, UK) using the small
volume sample dispersion unit. The refractive index and density of γ-Fe2O3-IONPs were set to 3.01
and 4.92 g mL−1, respectively, while the absorbance was set to 0.1. Additionally, the dh of 50 µL of
IONP suspensions at 200 µgFe mL−1 were measured at room temperature by centrifugal force with a
disc centrifuge (CPS Instruments, Oosterhout, Neatherland) at 22,000 rpm. The refractive index and
density of γ-Fe2O3-IONPs were set to 2.95 and 4.92 g mL−1, respectively, while the absorbance was set
to 0.1. A sucrose gradient from 8% up to 24% sucrose was used.
UV-visible spectra of IONP suspensions in water, RPMI medium and DMEM were measured at
concentrations of 100 µgFe mL−1 in Brand® UV-cuvettes with a Cary 100 Bio spectrometer (Agilent
Technologies, Waldbronn, Germany) between 190 and 900 nm. The average time was set to 0.1 s,
the data interval to 1 nm and the scan rate to 600 nm min−1.
IONP suspensions were lyophilized for four days with an alpha 1–2 Laboratory dryer (LD) plus
freeze dryer. Fourier transform IR (FTIR) spectra of IONPs powder pellets were obtained with the
Spectrum One spectrometer (series: 69288, Perkin Elmer, Schwerzenbach, Switzerland). Transmittance
from 4600 cm−1 to 400 cm−1 were given as the average of measured 64 scans for each curve with a
resolution of 4.00 cm−1.
X-ray Photoelectron Spectroscopy (XPS) measurements were carried out using a PHI VersaProbe
II scanning XPS microprobe (Physical Instruments AG, Meylan, France). Analysis was performed
using a monochromatic Al Kα X-ray source of 24.8 W power with a beam size of 100 µm. The spherical
capacitor analyser was set at a 45◦ take-off angle with respect to the sample surface. The pass energy
Nanomaterials 2017, 7, 202 14 of 19
was 46.95 eV yielding a full width at the half maximum of 0.91 eV for the Ag 3d 5/2 peak. Curve
fitting was performed using the PHI Multipak software (Blue Scientific, Cambridge, UK).
3.4. Binding Strength of PLP Chemical Groups on IONPs
In order to evaluate the binding strength of both the deprotonated and protonated phosphoryl
and phenolic groups to the surface of an IONP, the Quantum opEn-Source Package for Research in
Electronic Structure, Simulation, and Optimization (ESPRESSO) [62] package was used to perform DFT
calculations of a PLP molecule, which carries these groups, adsorbed to a (110) surface of magnetite
(Fe3O4). Despite the different iron-oxide phase, the magnetite surface can serve as a model for the
more complex maghemite surface, because the chosen surface is Fe3+ terminated [63] and has the same
ion arrangement, however without a random arrangement of oxygen vacancies. Thus, this surface
should be chemically similar to the ones exposed by a typical IONP. Orientations of the molecule were
chosen so that always only one of the functional groups interacted with the surface. Using the same
calculation setup as in Aschauer and Selloni [63], structures were relaxed until forces converged below
0.05 eV Å−1 and the adsorption energy was computed as: ∆Eads = − [Esurf+molec −(Esurf + Emolec)],
where Esurf+molec is the total energy of the surface with adsorbed molecule, while Esurf and Emolec
are the total energies of the isolated surface and molecule, respectively. Within this convention, a
positive adsorption energy indicates favourable binding to the surface. Figure 2 shows the final relaxed
configurations for the both chemical groups in the deprotonated and protonated states.
3.5. Cellular Uptake Study by TEM
LnCaP and PC3 cells were cultured in RPMI 1640 medium (American Type Culture Collection,
ATCC, Wesel, Germany) and DMEM GlutaMAX with 25 mM high glucose and 1 mM sodium
pyruvate (Gibco, Thermo Fisher Scientific, Darmstadt, Germany), both supplemented with 10%
fetal bovine serum (Life Technologies, Thermo Fisher Scientific, Darmstadt, Germany) and 1.5%
10,000 U mL−1 Penicillin Streptomycin (Life Technologies, Thermo Fisher Scientific, Darmstadt,
Germany). 40,000 LnCaP cells and 50,000 PC3 cells per well were cultured on plastic 13 mm diameter
sterile coverslips (NuncTM ThermanoxTM) in 12 well plates at 37 ◦C. Cells were exposed to 1 mL
of 100 µgFe mL−1 of IONPs for 24 h. Cells treated only with medium served as negative controls.
After 24 h, cells were washed three times with PBS and fixed for 1 h at room temperature with 2%
paraformaldehyde and 2.5% glutaraldehyde in PBS (pH 7.4). After 1 h, coverslips were washed three
times with 0.1 M cacodylate buffer (pH 7.4), stained with 1% osmium tetroxide in 0.1 M cacodylate
buffer at room temperature for 1 h and with 2% uranyl acetate in water for 40 min. After dehydrating
the coverslips with an increasing percentage of ethanol, up to 100%, they were then embedded in
50% durcupan (in ethanol) for 30 min and in 100% durcupan for 2 h. The resin was left to polymerize
overnight at 60 ◦C. The next day, the resin embedded samples were separated from the glass slides by
plunging them alternately into liquid nitrogen and hot water. The cells were then thin sectioned at
a thickness of 50 nm with a diamond knife (Diatome, Leica Mikrosysteme Vertrieb GmbH, Wetzlar,
Germany) and ultramicrotome (Leica Mikrosysteme Vertrieb GmbH, Wetzlar, Germany) and collected
on a formvar film on copper slot grids. Samples were imaged with a transmission electron microscope
operating at 80 kV (FEI, Gräfelfing, Germany, Tecnai Spirit, FEI, Gräfelfing, Germany).
3.6. In Vitro Toxicity Study by the MTS Assay
40,000 LnCaP cells per well were cultured in 96-well plates at 37 ◦C, and exposed to 100 µL of
different concentrations of IONPs (0, 1, 5, 10, 50 and 100 µgFe mL−1) for 24 h. Cells treated only with
medium served as negative controls. After 24 h incubation, the supernatant of each well were removed.
100 µL of MTS solution (CellTiter 96® Aqueous One Solution Cell Proliferation Assay from Promega,
diluted six times in medium) was added to the cells. After 2 h incubation, the absorbance of the
formazan product was measured with a microplate reader (Tecan Infinite M200, Tecan, Männedorf,
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Switzerland) at a wavelength of 490 nm. The cell viabilities were calculated as the absorbance in cells
treated with IONPs normalized with the absorbance of cells without IONPs (0 µgFe mL−1).
3.7. Cellular Uptake and Annexin V/PI In Vitro Toxicity Study by Flow Cytometry
350,000 LnCaP cells and 200,000 PC3 cells per well were cultured in six well plates, and exposed
to 2.5 mL of different IONP concentrations (0, 5, 10, 50 and 100 µgFe mL−1) for 24 h. Cells treated only
with medium served as negative controls, and cells treated with 10 µM of staurosporine (diluted from
1 mM solution in DMSO, Sigma-Aldrich, Taufkirchen, Germany) for 20 h and 2 mM H2O2 (diluted
from 3% stock solution, Fluka, Sigma-Aldrich, Taufkirchen, Germany) for 4 h were used as positive
controls. After 24 h incubation, cells were washed once with PBS and detached from the wells with
0.05% trypsin-EDTA (Gibco). Cells were centrifuged and resuspended in 100 µL of Annexin V Binding
Buffer (BioLegend, London, UK). 12.5 µL of 1/25 APC-Annexin V solution (BioLegend, London, UK)
were added to the cells, which were incubated for 25 min at room temperature in the dark. 5 µL of PI
and 100 µL of Annexin V Binding Buffer were then added. Samples were analyzed by flow cytometry
(Accuri C6, BD Biosciences, Allschwil, Switzerland). APC-Annexin V was detected with λexc = 640 nm
and λem = 675 ± 12.5 nm and PI was detected with λexc = 488 nm and λem = 585 ± 20 nm. The side
scattered (SSC) light was measured in function of the forward scattered (FSC) light, to determine the
cell granularity and consequently the cellular uptake of IONPs [36]. The cell viabilities are reported
as cells negative for both Annexin V and PI. For both the MTS test and the Annexin V/PI assay, all
experiments were performed in triplicate. Results are given as means (with standard deviations) of the
values obtained in these triplicates.
3.8. MRI
The IONPs were suspended in 2% agarose gel in 0.5 mL Eppendorf cups to obtain final
concentrations ranging from 0 to 30 µgFe mL−1. All cups were placed in a water-containing phantom
for subsequent T1 and T2 measurements, which were performed at room temperature on a 3.0 T
clinical MRI scanner (MAGNETOM Prisma, Siemens AG, Erlangen, Germany), and data was acquired
using a body array coil. The measurement of the longitudinal relaxation times T1 was performed
using a 2 dimensional spin echo sequence preceded by a 180◦ inversion pulse with different inversion
times (TI). Measurements of the transversal relaxation times T2 were performed with a 2D spin echo
sequence with variation of the echo time (TE). Imaging parameters for longitudinal relaxation times
T1 were as follows: TE 6.3 ms, slice thickness 5 mm, Field of View (FOV) 250 × 150 mm2, matrix
384 × 310, radiofrequency (RF) excitation angle 90◦, receiver bandwidth of 651 Hz/pixel, TI 23, 50, 75,
100, 125, 150, 175, 200, 300, 400, 500, 1000, 5000, 9000 ms. Imaging parameters for transversal relaxation
times T2: TE 6.3, 8, 10, 15, 20, 25, 30, 35, 65, 250 ms, slice thickness 5 mm, FOV 250 × 150 mm2, matrix
384 × 310, RF excitation angle 90◦, receiver bandwidth of 651 Hz/pixel. The magnetization was
allowed to recover for 15 s between acquisitions. The signal evolution S as function of TI and TE was
fitted to derive the T1 and T2 of each γ-Fe2O3 NPs suspension respectively, and is described as follows:
S(TE) = S(0)e−
TE
T2 + C (1)
S(TI) = S(0)(1− 2e−
TI
T1 ) (2)
The T1 and T2 values as function of their γ-Fe2O3 NPs concentration were subsequently fitted to
obtain the relaxivities r1 and r2 described as:
1
T1,2
=
1
T1,2[0]
+ r1,2[γ− Fe2O3] (3)
All data were analyzed and fitted with Matlab (The MathWorks, Natick, MA, USA).
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4. Conclusions
In this work we investigated for the first time the potential of PLP to be simultaneously used as a
coating molecule and targeting molecule via the direct attachment of PLP to IONPs. By controlling
the pH of the coating reaction, PLP was oriented differently at the IONPs’ surface, which resulted in
different physico-chemical properties of PLP-coated IONPs, such as surface charges, zeta potential,
hydrodynamic radius and agglomeration state. In addition, we didn’t observe any toxicity on both
LnCaP and PC3 cells, giving PLP interesting biocompatibility features for the coating of NPs for
medical applications. Furthermore, we measured high r2 values for the use of PLP-coated IONPs as
contrast agents for MRI. Importantly, we found that PLP controlled the interaction of IONPs with both
studied cell lines, LnCaP and PC3. In LnCaP cells, PLP modified the morphology and diameter of the
IONP-containing vesicles, while in PC3 cells the amount of IONPs taken up was different. Therefore,
the results of this study provide evidence that PLP can be used as a coating molecule and targeting
agent around IONPs, allowing us to tune the interaction of IONPs with cells. While the cellular uptake
of PLP has been so far poorly studied, we provide the first understanding of the effect of PLP bound
to IONPs in this process. Further studies on the biodistribution, blood circulation or metabolism of
PLP-coated IONPs could provide more insights into the potential use of PLP as a coating and targeting
molecule for various medical applications.
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